Clinical Trial Update: Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating camrelizumab plus amlotinib and chemotherapy as first-line treatment for melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• amlotinib (amlotinib)

Snippet

Sponsor: Di Wu | Conditions: Melanoma | Phase 2 | Status: UNKNOWN